Ovarian hormones and vascular disease

Current Opinion in Cardiology

Volumn 28, Issue 4, 2013, Pages 411-416

  Hage, Fadi G ^a,b   Oparil, Suzanne ^a  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

estrogen; inflammation; oxidative stress; smooth muscle cells; vascular injury

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GENISTEIN; GESTAGEN; GLYCOSYLATED HEMOGLOBIN; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOESTROGEN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGING; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CEREBROVASCULAR ACCIDENT; CHROMATIN IMMUNOPRECIPITATION; CLIMACTERIUM; CLINICAL STUDY; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; EARLY MENOPAUSE; ESTROGEN RELEASE; FEMALE; FOLLOW UP; GENE EXPRESSION; GLUCOSE TOLERANCE; HEART PROTECTION; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MENOPAUSAL SYNDROME; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; UTERUS MYOMA; UTERUS PROLAPSE; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; VASCULITIS; VASODILATATION; VASOPROTECTION;

AGE FACTORS; ANIMALS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; VASCULAR DISEASES;

EID: 84879952303     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32836205e7     Document Type: Review

References (40)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics: 2013 Update-a report from the American Heart Association. Circulation 2013; 127:e6-e245.
2. Bowling M, Oparil S, Hage FG, et al. Sex hormones and vascularfunction. In: Sex hormones. Edited by: Dubey RK. Rijeka, Croatia: In Tech; 2012. ISBN: 978-953-307-856-4. http://www.intechopen.com/books/sex-hormones/sex-hormones- and-vascular-function. [Accessed 22 April 2013]
3. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133:933-941.
4. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
5. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replace-ment Study follow-up (HERS II). JAMA 2002; 288:49-57.
6. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the riskof coronary heart disease. N Engl J Med 2003; 349:523-534.
7. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005; 83:558-566.
8. Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of meno-pausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011; 124:199-205.
9. Xing D, Nozell S, Chen YF, et al. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009; 29:289-295.
10. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166:357-365.
11. La Croix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305-1314.
12. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormonetherapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-1477.
13. Toh S, Hernandez-Diaz S, Logan R, et al. Coronary heart disease in post-menopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010; 152:211-217.
14. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Data-base Syst Rev 2012; CD004143.
15. Wellons M, Ouyang P, Schreiner PJ, et al. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 2012; 19:1081-1087.
16. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk ofcardiovasculardisease.Arch Intern Med 1999; 159:1061-1066.
17. van der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Ageatmenopause as a risk factor for cardiovascular mortality. Lancet 1996; 347: 714-718.
18. Lisabeth LD, Beiser AS, Brown DL, et al. Ageat natural menopauseand riskof ischemic stroke: the Framingham heart study. Stroke 2009; 40:1044-1049.
19. Kuh D, Langenberg C, Hardy R, et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG 2005; 112:476-485.
20. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345:e6409.
21. Miller VM, Black DM, Brinton EA, et al. Using basicsciencetodesign aclinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009; 2:228-239.
22. Manson JE. The kronos early estrogen prevention study by Charlotte Barker. Womens Health (Lond Engl) 2013; 9:9-11.
23. Shufelt CL, Johnson BD, Berga SL, et al. Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evalua-tion. Menopause 2011; 18:943-950.
24. Novella S, Heras M, Hermenegildo C, Dantas AP. Effects of estrogen on vascular inflammation: amatteroftiming. Arterioscler Thromb Vasc Biol 2012; 32:2035-2042.
25. Novensa L, Novella S, Medina P, et al. Aging negatively affects estrogens-mediated effects on nitric oxide bioavailability by shifting ERalpha/ERbeta balance in female mice. PLo S One 2011; 6:e25335.
26. Xing D, Feng W, Miller AP, et al. Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-betaactivation. Am J Physiol Heart Circ Physiol 2007; 292:H2607-2612.
27. Xing D, Oparil S, Yu H, et al. Estrogen modulates NFkappa B signaling by enhancing Ikappa Balpha levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-beta. PLo S ONE 2012; 7:e36890.
28. Weber C. Micro RNAs: From basic mechanisms to clinical application in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2013; 33:168-169.
29. Bhat-Nakshatri P, Wang G, Collins NR, et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 2009; 37:4850-4861.
30. Pan Q, Luo X, Chegini N. Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med 2008; 12:227-240.
31. Zhao J, Imbrie GA, Baur WE, et al. Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2013; 33:257-265.
32. Viticchie G, Lena AM, Latina A, et al. Mi R-203 controls proliferation, migration and invasivepotential of prostatecancer cell lines. Cell Cycle 2011;10:1121-1131.
33. Yuan Y, Zeng ZY, Liu XH, et al. Micro RNA-203 inhibits cell proliferation by repressing Delta Np63 expression in human esophageal squamous cell carcinoma. BMC Cancer 2011; 11:57.
34. Meyer MR, Haas E, Prossnitz ER, Barton M. Nongenomic regulation of vascular cell function and growth by estrogen. Mol Cell Endocrinol 2009; 308:9-16.
35. Levin ER. Membrane oestrogen receptor alpha signalling to cell functions. J Physiol 2009; 587:5019-5023.
36. Bernelot Moens SJ, Schnitzler GR, Nickerson M, et al. Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation 2012; 126:1993-2004.
37. Chambliss KL, Wu Q, Oltmann S, et al. Nonnuclear estrogen recep-tor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 2010; 120:2319-2330.
38. Wang S, Zhu X, Cong B, et al. Estrogenic action on arterial smooth muscle: permissive for maintenance of CRHR2 expression. Endocrinology 2012; 153:1915-1924.
39. Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011; 7:715-726.
40. Meyer MR, Field AS, Kanagy NL, et al. GPER regulates endothelin-dependent vascular tone and intracellular calcium. Life Sci 2012; 91: 623-627. Service Merit Award